Cytori Therapeutics price target raised to $6 from $3.50 at Roth Capital Roth Capital increased its price target on Cytori after the company received final FDA approval for a clinical trial of its treatment for scleroderma., and the firm attended an event hosted by the company with a scleroderma expert. Roth says that the expert highlighted the unmet medical need in scleroderma as well its significant morbidity and mortality. The firm expects the company's visibility to improve this year, and it keeps a Buy rating on the stock.
Cytori Therapeutics price target raised to $6 from $3.50 at Roth Capital Roth Capital raised its price target for Cytori Therapeutics to $6 and keeps a Buy rating on the name. The stock is rating up 3% to 46c.